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Abstract
Background: Fanconi anaemia is a rare inherited disease characterized by congenital abnormalities, progressive bone
marrow failure and predisposition to malignancy. Successful pregnancies in transplanted patients have been reported.
In this paper we will describe the pregnancy of a patient with Fanconi anaemia without transplantation.
Case presentation: A 34-year-old nulliparous woman with Fanconi anaemia was referred to our institution. Pregnancy
was complicated by progressive pancytopenia and two severe infections. C-section was performed at 36 weeks. Both
infant and mother are well.
Conclusion: Successful pregnancy in a Fanconi anaemia patient with bone marrow failure is possible. The mode of
delivery in patients with bone marrow failure should be determined by obstetric indications. The case highlights the
safe outcome of the pregnancy with strict clinical and laboratory control by a multidisciplinary team.
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Background
Fanconi anaemia (FA) is a heterogeneous genetic syn-
drome characterized by congenital abnormalities, bone
marrow failure (BMF), with an increased cancer occur-
rence [1]. Hematopoietic stem cell transplant (HSCT)
using an adapted attenuated conditioning regimen, is the
only curative treatment in the event of BMF [1]. Published
reports show that if pregnancy occurs in FA patients after
HSCT, it has a favourable outcome [1]. The effect of preg-
nancy in non-transplanted FA patient is unknown and
pregnancy outcome has never been reported. Below is the
description of the first case of a pregnancy in a non-
transplanted FA patient.
Case presentation
We report a female patient initially diagnosed with FA at
age 11 years. The patient did not undergo HSCT due to
lack of combined donator availability. She received
periodically supportive care with leucocyte depleted and
irradiated packed red blood cell (PRBC) and platelet
transfusions to maintain a safe blood count.
She became pregnant naturally at 35 years old and she
was referred to our institution at 8 weeks. Laboratory
tests showed pancytopenia with severe neutropenia and
thrombocytopenia (haemoglobin 9.1 mg/dL, leukocytes
1.86 × 109/L, platelets 27 × 109L). We discussed with the
patient the benefits and risks of both induced abortion
and continuing the pregnancy including the high prob-
ability of miscarriage, severe infections during the preg-
nancy, placental abruption and that pregnancy may be a
precipitating factor for FA. The patient decided to con-
tinue the pregnancy. A weekly outpatient consultation
was scheduled during which the pregnancy and patient’s
blood tests were evaluated. Over time, pancytopenia pro-
gressed (Fig. 1a). PRBC and platelet transfusions were
performed weekly to maintain haemoglobin level above
of 9–10 mg/dL and platelet count above 10 × 109/L in
the first trimester and then of 5 × 109/L.
At 15 weeks, she was admitted to our hospital with
fever (102.2°F), diarrhoea and rectal bleeding. Leukocytes
were 0.65 × 109/L with 10% of neutrophils, platelet count
was 13 × 109/L, C-reactive protein (CRP) level was
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Fig. 1 The pattern of maternal laboratory values (hemoglobin, leukocytes and platelet count) in association with component transfusion therapy (packed
red blood cell and platelets) from 8 weeks of gestation to 34 weeks of gestation a and during patient’s last hospital stay b PRBC = packed red blood cells
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180 mg/dl. Echocardiogram, chest radiography, blood and
urine cultures were negative. Stool culture was positive for
Campilobacter Jejuni. A peripheral inserted central cath-
eter (PICC) line was inserted in order to prevent frequent
venepuncture. Vancomycin 1 g every 8 h and Azithromy-
cin 500 mg every 12 h were started. After three days of
antibiotic therapy fever, diarrhoea and rectal bleeding
stopped. We proposed a dose of Granulocyte colony-
stimulating factor (G-CSF) but the patient refused. During
hospitalization she received eight PRBC and six platelet
transfusions, although survival of transfused platelets rap-
idly declined and she became refractor. At 20 weeks she
was discharged.
At 25 weeks, she was diagnosed with gestational dia-
betes mellitus (GDM). We developed a customized self-
monitoring of blood glucose and diet plan. Then, at
30 weeks an insulin treatment was added.
At 34 + 3 weeks she once again had high level of CRP
(42 mg/dl) and was hospitalized. Blood culture was posi-
tive for Escherichia Coli infections. Ceftriaxone 2 g intra-
venous (IV) daily was started with a progressive reduction
of CRP level. A caesarean section (CS) under general an-
aesthesia was scheduled at 35 + 6 weeks under cover infu-
sion of three unit of PRBC and three of platelet 48 h
before surgery to obtain haemoglobin level above 9 g/dL
and platelet count above 5 × 109/L (Fig. 1b). After
ultrasound-guided placement of a jugular central venous
catheter, patient was taken into the operating theatre.
Three units of platelets were infused before induction,
followed by two units of PRBC. Anaesthesia was induced
with Propofol IV 150 mg, Remifentanil IV 0.25 μg/kg/min
and Rocuronium IV 100 mg. Thereafter, anaesthesia was
maintained with 0.22 μg/kg/min of Remifentanil IV. A
male infant weighing 2,740 g was delivered. The baby was
intubated and transferred to the neonatal intensive care
unit. The Apgar scores for the baby were 3 and 7 at 1 and
5 min respectively. Umbilical cord arterial pH was 7.26.
The baby was extubated after two hours uneventfully. Pa-
tient maintained stable hemodynamics intraoperatively
and total blood loss was 400 ml. A bolus of ten inter-
national unit (IU) oxytocin followed by a 40 IU oxytocin
infusion was administrated. At the end of procedure
neuromuscular blockade were reversed with Sugammadex
500 mg IV. Following surgery, the patient was shifted to
Post-operative Anaesthesia Care Unit (PACU). Antibiotics
were continued with Augmentin IV 2.2 g 12 h. Enoxaparin
4000 international unit daily was started after 12 h from
CS. Two units of PRBC and two units of platelets were
transfused. On the second post-operative day (POD) pa-
tient was released from PACU. She once again developed
a fever (100°F). Blood cultures were positive for Staphylo-
coccus hominis. Meropenem 1 g IV every 8 h and Vanco-
mycin every 12 h were started. On the sixth POD she was
apyretic and was discharged on day ten.
Discussion and conclusions
The natural history of FA ends in lethal BMF. HSCT,
using an adapted attenuated conditioning regimen, is the
only curative treatment when BMF occurs. In the last
decade, the conditioning has been reduced because of
the toxic effect of alkylating agents, making a normal
ovarian function recovery and a viable pregnancy pos-
sible [1]. Our patient did not receive HSCT and decided
to continue her pregnancy, although she had already de-
veloped BMF.
To our knowledge, there is no published data in rela-
tion to pregnancy in women with FA without HSCT.
We relied on studies on women with aplastic anaemia
(AA). AA is a pancytopenia associated with unexplained
hypocellularity of the bone marrow. In literature there
are many reports on pregnancy with AA, and this dis-
order is quite similar to our patient’s [2–4]. Data shows
that patients presenting severe AA in early pregnancy
should be offered termination because this may be
followed by haematological improvement and because
the poor maternal and fetal outcomes. Pregnant patients
with thrombocytopenia are at high risk of miscarriages,
placental abruption preeclampsia/eclampsia, preterm de-
livery, intrauterine growth restriction, fetal death, neo-
natal and maternal death [3]. Two studies on AA in
pregnancy reported that platelet count is the main risk
factor for obstetrics and desease complications [3, 4].
Most authors agree that 50 × 109/L is the cut-off for
therapy in asymptomatic patients [5]. Treatment is also
required in patients with counts greater than 50 × 109/L
and bleeding complications as well as conditions associ-
ated with impaired haemostasis, such as fever [5]. Our
patient began her pregnancy with a platelet count of
27 × 109/L and thrombocytopenia was aggravated during
pregnancy. She received weekly platelet transfusions, al-
though from the second trimester she became refractory.
Refractoriness to platelet transfusion is a common con-
dition in patients receiving frequent platelet transfusions.
An on-going process of transfused platelet destruction
has been reported in severe thrombocytopenia [5].
Therefore, we decided to perform platelet transfusions
only with platelet count less then 5 × 109/L or with
bleeding and/or fever. Moreover, due to bleeding ten-
dency of the patient, we adopted prophylactic strategies
such as a personalized self-monitoring of blood glucose
scheme for the management of GDM. Intramuscular ad-
ministrations were avoided.
Turning to neutropenia, this condition is defined as per-
ipheral blood absolute neutrophil counts (ANC) below
1.5 × 109/L. Authors reported an increase in neutrophil
counts during pregnancy in patients with AA [3, 4]. This
may explain why sepsis is a rare complication in these pa-
tients. Our patient developed a severe form of neutropenia
(ANC below 0,5 × 109/L) in the second trimester reaching
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a nadir of 0.06 × 109/L at 15 weeks and then the neutro-
phil count partially recovered (Fig. 1). G-CSF has been
shown to improve the neutropenia of patients with BMF.
A recent retrospective study on 38 pregnancies with se-
vere neutropenia demonstrated that the use of G-CSF
throughout pregnancy was safe and well tolerated [6]. Our
patient developed intestinal infection in the second tri-
mester, a lower urinary tract infection at 35 weeks and a
positive blood culture in postpartum. The patient refused
G-CSF treatment. Even if infections were successfully
managed with antibiotics, we believe G-CSF therapy could
have been useful.
The patient also had severe anaemia and she received
weekly PRBC transfusions. An association between severe
anaemia (haemoglobin < 9 g/dL) and poor pregnancy out-
come has been reported by multiple observational studies.
A recent metanalysis of 44 cohort studies showed a sig-
nificantly higher risk of low birth weight and preterm
birth in patients with anaemia in the first or second tri-
mester [7]. Our patient did not develop either fetal growth
restriction or preterm labour, most likely due to the fact
that her haemoglobin level remained above 9 mg/dl dur-
ing pregnancy (Fig 1a).
This case was also an anaesthesiology challenge. As
patients with thrombocytopenia should avoid invasive pro-
cedures such as venepuncture, a PICC was inserted during
her first hospital stay [8]. It was used for intravenous fluids,
antibiotics and to get blood samples; no complications
occurred. This venous device was chosen as it has low inci-
dence of infection and because of its low risk insertion pro-
cedure [8]. General anaesthesia was preferred over regional
anaesthesia as there was a risk of spinal hematoma, due to
severe thrombocytopenia. Furthermore, it would have been
easier to manage severe blood loss if patient was under gen-
eral anaesthesia and well oxygenated.
Concerning the mode of delivery, several investigations
have stated that in patients with thrombocytopenia the
mode of delivery should be determined by obstetric indica-
tions. Although some authors have concern about the risk
of spontaneous intracranial haemorrhage in AA patient
during labour, vaginal delivery should be the preferred
route of delivery since it involves less loss of blood, as well
as less risk of infections [3]. We decided to perform CS for
several reasons. First, the risk of sepsis outweighed the
benefit of continuing the pregnancy and a preterm delivery
was necessary. Second, the patient was a preterm primi-
gravida and induction of labour would have been unlikely
successful. Finally, the date of CS was arranged two days
before in order to have availability of an adequate supplies
of blood products.
In conclusion, improvement in supportive treatment of
FA with BMF has prolonged survival and the outlook for
women to reach childbearing years is far more optimistic,
than it once was. This report shows that in this high-risk
patient, despite the occurrence of severe complications,
pregnancy was possible without either maternal or fetal se-
quela. The pregnancy of our patient was managed by a
multidisciplinary team (gynaecologists, haematologists and
anaesthesiologists). Thrombocytopenia and neutropenia
were the most challenging issues. Supportive therapy con-
sisted of a total of 42 units of PRBC and 22 units of platelet
as well as precautions against infection. We believe herein-
after information on pregnancy and disease outcome could
be more accurate in non-transplanted FA patient counsel-
ing due to our experience.
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